Clinical Trials Logo

Filter by:
NCT ID: NCT04846244 Not yet recruiting - Clinical trials for Radiographic Axial Spondylarthritis (r-axSpA)

A Study of the Change in Early and Sustained Pain Control in Radiographic Axial Spondylarthritis in Adult Participants Receiving Upadacitinib

UPSTAND
Start date: April 15, 2021
Phase:
Study type: Observational

Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain (IBP) that might be difficult to distinguish from other causes of chronic back pain (CBP). Many participants report persistent pain, including back pain, which impacts disease activity and quality of life including creating burdens such as sleep disturbance, social isolation, loss of productivity, as well as anxiety and depression. Despite this, there is a lack of detailed data and knowledge on pain in radiographic-axial spondyloarthritis (r-axSpA), including pain types, how it is localized, and how these different facets of pain are impacted by treatment. This study will assess the real-world effectiveness of upadacitinib on early and sustained pain control, and the association between pain and clinical/patient-reported outcomes in radiographic axSpA participants. Upadacitinib is being developed for the treatment of r-axSpA. Approximately 877 adult participants with activer-axSpA will be enrolled across approximately 19 countries in Europe, North America, South America, and Asia-Pacific. Participants will receive oral upadacitinib tablets as prescribed by the physician prior to enrolling in this study in accordance with the terms of the local marketing authorization and professional and reimbursement guidelines with regards to dose, population and indication. The overall duration of the study is approximately 30 months. There may be a higher burden for participants in this study compared to usual standard of care. Participants will attend regular visits per routine clinical practice. The effect of the treatment will be checked by medical assessments, checking for side effects, and questionnaires.

NCT ID: NCT04844073 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer

Start date: March 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary antitumor activity of MVC-101

NCT ID: NCT04841512 Not yet recruiting - Clinical trials for Osteoarthritis, Spine

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

Start date: July 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

NCT ID: NCT04840784 Not yet recruiting - Leukemia Clinical Trials

First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Start date: April 2021
Phase: Phase 1
Study type: Interventional

This Trial is a FIH, open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with R/R B-cell NHL, CLL/SLL and AML who previously received standard treatment or are ineligible for standard treatment options.

NCT ID: NCT04840667 Not yet recruiting - Fabry Disease Clinical Trials

A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Start date: July 9, 2021
Phase: Phase 3
Study type: Interventional

In this study, adults with Fabry Disease who have not had any treatment for this condition will be treated with Replagal. The main aim of the study is to check if Replagal improves kidney function and heart structure of participants with Fabry Disease. Participants will receive one Replagal infusion every other week for up to 104 weeks. They will visit the clinic every 12 to 14 weeks during treatment with a follow-up visit 2 weeks after treatment.

NCT ID: NCT04840147 Not yet recruiting - Clinical trials for Articular Cartilage Disorder of Knee

A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea,

JMAC
Start date: April 2021
Phase: N/A
Study type: Interventional

The aim of the study is to compare whether JointRep® plus microfracture is more effective than microfracture alone when treating symptomatic focal articular cartilage lesions in the knee (femoral condyles or trochlea).

NCT ID: NCT04839783 Recruiting - Clinical trials for Degenerative Disc Disease

Single Position Spine Surgery Registry

SPSG Registry
Start date: July 7, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to systematically, prospectively compare surgical fusion techniques for thoracolumbar spinal fusion patients and assess long-term patient outcomes and revision rates following surgery.

NCT ID: NCT04839367 Not yet recruiting - Prostatic Neoplasms Clinical Trials

Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA

PROPELLER
Start date: April 2021
Phase: Phase 1
Study type: Interventional

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

NCT ID: NCT04839042 Not yet recruiting - Covid19 Clinical Trials

A Phase 1, First-In-Human Study, to Assess the Safety, Reactogenicity, and Immunogenicity of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers

Start date: June 1, 2021
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, first-in-human, single ascending dose and multiple dose study to assess the safety, reactogenicity, and immunogenicity of the SC-Ad6-1 investigational product when administered via intramuscular (IM) route in healthy volunteers.

NCT ID: NCT04838405 Recruiting - Diabetes Clinical Trials

A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.